Gastric amphicrine carcinoma with leptomeningeal metastases: A case report

doi:10.4251/wjgo.122768

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 9

This Article

(13)

(9)

(0)

(7)

(147)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Sep 15, 2026; 18(9): 122768
Published online Sep 15, 2026. doi: 10.4251/wjgo.122768

Table 1 Whole course of the therapeutic regimens

Initiation of therapy to disease progression	Therapeutic stage	Therapeutic regimen	Medication usage	PFS (month)
April 17, 2025 to September 26, 2025	First-line therapy	SOX + tislelizumab	Oxaliplatin 120 mg, ivggt, d1; S1: 40 mg, po, bid, d1-14; tislelizumab 200 mg, ivggt, d1; a 21-day cycle	5
September 28, 2025 to November 27, 2025	Second-line therapy	FOLFIRI + tislelizumab	Irinotecan 200 mg, ivggt, d1; calcium folinate 300 mg, ivggt, d1; 5-fluorouracil 500 mg, bolus, d1; 5-fluorouracil 3000 mg, CIV, 46 hours; a 14-day cycle; tislelizumab 200 mg, ivggt, d1; a 21-day cycle	2
December 5, 2025 to January 22, 2026	Third-line therapy	Abraxane + zotuximab	Abraxane 200 mg, ivggt, d1; zotuximab 1000 mg as initial dose, 600 mg as maintenance dose, ivggt, d1; a 21-day cycle	1.6

CIV: Continuous intravenous infusion; ivggt: Intravenous guttae; PFS: Progression-free survival; S1: Tegafur gimeracil oteracil potassium capsule.

Full Size Table

Citation: Deng C, Shi YF, Guo WJ, Wang C, Chen DM, Tan HY. Gastric amphicrine carcinoma with leptomeningeal metastases: A case report. World J Gastrointest Oncol 2026; 18(9): 122768
URL: https://www.wjgnet.com/1948-5204/full/v18/i9/122768.htm
DOI: https://dx.doi.org/10.4251/wjgo.122768

Deng C, Shi YF, Guo WJ, Wang C, Chen DM, Tan HY. Gastric amphicrine carcinoma with leptomeningeal metastases: A case report. World J Gastrointest Oncol 2026; 18(9): 122768 [DOI: 10.4251/wjgo.122768]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.